Overview
The purpose of this registry study is to create a database-a collection of information-for better understanding T-cell lymphoma. Researchers will use the information from this database to learn more about how to improve outcomes for people with T-cell lymphoma.
Eligibility
Inclusion Criteria:
- Written informed consent
- Adequate fresh or archival tumor biopsy or intent to obtain fresh tumor biopsy.
- Pathologically-confirmed mature T- or natural killer (NK)-cell lymphoma meeting one of
the following diagnostic criterion (based on WHO classification and NCCN guidelines):
- T-cell prolymphocytic leukemia
- T-cell large granular lymphocytic leukemia
- Chronic lymphoproliferative disorder of NK cells
- Aggressive NK-cell leukemia
- Systemic Epstein-Barr virus (EBV)-positive T-cell lymphoma of childhood
- Chronic active EBV infection of T- and NK-cell type, systemic form
- Hydroa vacciniforme-like lymphoproliferative disorder
- Adult T-cell leukemia/lymphoma
- Extranodal NK/T-cell lymphoma, nasal type
- Enteropathy-associated T-cell lymphoma
- Monomorphic epitheliotropic intestinal T-cell lymphoma
- Intestinal T-cell lymphoma, not otherwise specified (NOS)
- Indolent T-cell lymphoproliferative disorder of the gastrointestinal tract
- Hepatosplenic T-cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma
- Mycosis fungoides (limited to those with ≥ stage IB disease and those receiving active therapy)
- Sézary syndrome
- Primary cutaneous anaplastic large cell lymphoma (receiving systemic therapy)
- Primary cutaneous Gamma-Delta T-cell lymphoma
- Primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma
- Primary cutaneous acral CD8+ T-cell lymphoma (receiving systemic therapy)
- Peripheral T-cell lymphoma, not otherwise specified
- Angioimmunoblastic T-cell lymphoma
- Follicular T-cell lymphoma
- Nodal peripheral T-cell lymphoma with TFH phenotype
- Anaplastic large cell lymphoma, ALK-positive
- Anaplastic large cell lymphoma, ALK-negative
- Breast-implant associated anaplastic large cell lymphoma.
- NOTE: Patients with diagnoses of mycosis fungoides, primary cutaneous anaplastic large
cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma must be receiving systemic therapy.
Exclusion Criteria:
- Patients with of mycosis fungoides, primary cutaneous anaplastic large cell lymphoma, and/or primary cutaneous acral CD8+ T-cell lymphoma not receiving systemic therapy.
- Inability to collect prospective data, measure response, or perform adequate follow-up assessments in the clinical judgment of the treating physician. NOTE: Repository participation does not exclude participation in clinical trials, nor does existing clinical trial participation exclude enrollment in the study herein outlined.